Drug Information

Drug General Information
Drug ID
D0W1SP
Former ID
DNC008915
Drug Name
(Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529444]
Formula
C20H27NO3
Canonical SMILES
CCCCCCCCCCN1C2=CC=CC=C2C(=CC(=O)O)C1=O
InChI
1S/C20H27NO3/c1-2-3-4-5-6-7-8-11-14-21-18-13-10-9-12-16(18)17(20(21)24)15-19(22)23/h9-10,12-13,15H,2-8,11,14H2,1H3,(H,22,23)/b17-15-
InChIKey
LIUQXAWYSKFADK-ICFOKQHNSA-N
PubChem Compound ID
44576974
Target and Pathway
Target(s) M-phase inducer phosphatase 1 Target Info Inhibitor [529444]
KEGG Pathway Cell cycle
Progesterone-mediated oocyte maturation
MicroRNAs in cancer
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database E2F transcription factor network
ATR signaling pathway
Validated targets of C-MYC transcriptional activation
ATM pathway
Reactome E2F mediated regulation of DNA replication
G0 and Early G1
Polo-like kinase mediated events
Cyclin B2 mediated events
Activation of ATR in response to replication stress
Cyclin E associated events during G1/S transition
G1/S-Specific Transcription
Cyclin A/B1 associated events during G2/M transition
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
Cyclin A:Cdk2-associated events at S phase entry
WikiPathways DNA Damage Response
G1 to S cell cycle control
S Phase
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Mitotic G1-G1/S phases
Cell Cycle
Cell Cycle Checkpoints
miRNAs involved in DNA damage response
miRNA Regulation of DNA Damage Response
References
Ref 529444Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. Epub 2008 Apr 15.Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors.
Ref 529444Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. Epub 2008 Apr 15.Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.